Bruker Corporation Unveils Revolutionary timsOmni Mass Spectrometer, Transforming Proteoform Research and Disease Study with Unprecedented Speed and Depth
Bruker Corporation has unveiled the timsOmni™ system, a groundbreaking mass spectrometer designed to revolutionize scientific research and drug discovery. This timsTOF-based instrument offers unparalleled speed and sensitivity, providing deep structural insights into functional and pathological proteoforms. Notable for its 'Swiss Army Knife' flexibility, the timsOmni facilitates advanced electron and collision induced ion fragmentation, aiding in proteoform sequencing and post-translational modification identification. This novel platform is set to transform disease research, biologics development, and quality control processes, offering critical insights into the structural changes of proteins associated with diseases such as cancer and neurodegeneration.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250530372173) on May 30, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。